TY  - BOOK
AU  - Matthews,Donna E.
TI  - Bile duct cancer: symptoms, treatment, and prognosis 
T2  - cancer etiology, diagnosis and treatments
SN  - 9781634847247
AV  - RC280.B48 
U1  - 616.99/436 23
PY  - 2016///]
CY  - New York
PB  - Nova Biomedical
KW  - Bile ducts
KW  - Cancer
KW  - Bile Duct Neoplasms
KW  - HEALTH & FITNESS / Diseases / General
KW  - bisacsh
KW  - MEDICAL / Clinical Medicine
KW  - MEDICAL / Diseases
KW  - MEDICAL / Evidence-Based Medicine
KW  - MEDICAL / Internal Medicine
KW  - fast
KW  - Electronic books
N1  - Includes bibliographical references and index; BILE DUCT CANCER SYMPTOMS, TREATMENT AND PROGNOSIS ; BILE DUCT CANCER SYMPTOMS, TREATMENT AND PROGNOSIS ; CONTENTS ; PREFACE; Chapter 1 CHOLANGIOCARCINOMA: SYMPTOMS AND CURRENT STATE OF MEDICAL AND SURGICAL MANAGEMENT ; ABSTRACT; INTRODUCTION; SYMPTOMS ; TREATMENT; INTRAHEPATIC CHOLANGIOCARCINOMA ; HILAR CHOLANGIOCARCINOMA AND EXTRAHEPATIC CHOLANGIOCARCINOMA ; PROGNOSIS ; REFERENCES ; Chapter 2 EXTRA HEPATIC CHOLANGIOCARCINOMA: SYMPTOMS, TREATMENT AND PROGNOSIS ; ABSTRACT ; EPIDEMIOLOGY ; RISK FACTORS ; CLINICAL PRESENTATION ; DIAGNOSTIC WORK-UP ; ANATOMY; LABORATORY INVESTIGATIONS IMAGING ; Ultrasound (US) ; Computed Tomography (CT)/Multi-Detector Computed Tomography (MDCT) ; Magnetic Resonance Imaging (MRI) ; Endoscopic Retrograde Cholangiopancreatography (ERCP)/Percutaneous Transhepatic Cholangiography (PTC) ; Endoscopic Ultrasonography (EUS)/Intraductal Ultrasonography (IDUS) ; Positron Emission Tomography (PET) ; Biopsy ; Staging ; Treatment; Distal Cholangiocarcinoma ; Perihilar Cholangiocarcinoma ; Preoperative Liver Evaluation/Interventions ; TREATMENT OF BILIARY OBSTRUCTION ; Adjuvant Therapies; Neoadjuvant Therapy and Transplantation Palliative Treatment ; REFERENCES ; Chapter 3 PREVALENCE OF BILE DUCT CANCER AS MEASURED BY DISCHARGES FROM DIAGNOSIS-PROCEDURE-COMBINATION (DPC) PARTICIPATING HOSPITALS AMONG BENEFICIARIES OF A PRINTING INDUSTRY HEALTH INSURANCE SOCIETY IN COMPARISON WITH GENERAL POPULATION ; ABSTRACT ; INTRODUCTION ; SUBJECTS AND METHODS ; 1. DPC Data from General Population ; 2. DPC data from HISPI; 3. Analysis ; 4. Ethical Approval ; RESULTS ; DISCUSSION ; ACKNOWLEDGMENTS ; REFERENCES ; Chapter 4 MEDICAL TREATMENT OF ADVANCED BILIARY TRACT CANCER ; ABSTRACT; 1.1. INTRODUCTION 1.2. CHEMOTHERAPY IN ADVANCED BILIARY TRACT CANCER ; 1.2.1. Combinations of Gemcitabine and Platinum Derivatives ; 1.2.2. Combinations of Gemcitabine and Fluoropyrimidines ; 1.2.3. Triple-Drug Chemotherapy Regimens; 1.2.4. S-1 Based Combinations ; 1.2.5. Second-Line Chemotherapy ; 1.3 TARGETED THERAPIES IN ADVANCED BILIARY DUCT CANCER ; 1.3.1. Therapies Targeting EGFR Pathway ; 1.3.1.1. Erlotinib; 1.3.1.2. Cetuximab ; 1.3.1.3. Panitumumab; 1.3.1.4. Afatinib ; 1.3.2. Therapies Targeting the VEGF Pathway ; 1.3.2.1. Bevacizumab ; 1.3.2.2. Sunitinib ; 1.3.2.3. Cediranib; 1.3.2.4. Sorafenib1.4. IMMUNOTHERAPY IN BILIARY TRACT CANCER ; 1.4.1. Tumor-Associated-Antigens ; 1.4.2. Checkpoint Inhibitors ; 1.4.3. How Can We Explain an Enhanced Immune Response in Biliary Cancers? ; CONCLUSION ; REFERENCES ; BIOGRAPHICAL SKETCH ; INDEX
UR  - https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258682
ER  -